Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

discStyle" type="disc">
  • On August 24, 2011 Shire announced its preliminary analysis of the top-line results from ABH's Phase 3 pivotal trial of DERMAGRAFT in subjects with VLU. The international pivotal trial was designed as a prospective, multicenter, randomized, controlled clinical study to assess the product's safety and efficacy in the promotion of healing VLU. The preliminary analysis of the data was that the trial did not meet the primary endpoint mutually agreed with the FDA and European Medicine Agency.

  •  

    VYVANSE® - for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD")

    • On October 21, 2011 Shire reported positive top line results of the first European Phase 3 study of once-daily lisdexamfetamine dimesylate ("LDX") in children and adolescents aged 6 to 17 years with ADHD. The study, conducted at 48 sites across Europe, demonstrated that a once-daily morning dose of LDX resulted in positive efficacy results on the primary as well as key secondary endpoints compared to placebo, and a safety profile consistent with the known effects of amphetamine treatment and previous LDX trials. In the study, patients were randomized to receive LDX, osmotic-controlled extended-release methylphenidate ("OROS-MPH"; marketed as CONCERTA® and CONCERTA XL® by Johnson & Johnson) or placebo, over a period of seven weeks. The CONCERTA arm was included in order to provide data versus the current European standard of care as it is often required for approval and to support appropriate reimbursement. The primary measure was the change in total score of the ADHD-RS-IV of LDX versus placebo with OROS-MPH included as an active control.


     

    VYVANSE - for the treatment of inadequate response in Major Depressive Disorder ("MDD")

    • Today, in the live conference call for investors
      '/>"/>

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
    2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
    3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
    4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
    5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
    6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
    7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
    8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
    9. Reportlinker Adds Shire plc: PharmaVitae Profile
    10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
    11. Shire plc - Statement re ProAmatine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife Solutions , ... and marketer of proprietary clinical grade hypothermic storage ... shipping products for cells and tissues  ("BioLife" or the ... Meeting of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
    (Date:12/24/2014)... GMO corn cases filed across the United ... process of being consolidated in a Kansas federal court for ... MIR 162 Corn Litigation, MDL No. 2591 in the U.S. ... the Syngenta GMO corn multidistrict litigation (MDL) has been handed ...
    (Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
    (Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
    Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
    ... CAMBRIDGE, Mass., May 21 Biopure Corporation,(Nasdaq: BPUR ... fiscal,quarter ended April 30, 2008. For the quarter, the ... per common share, compared with a net loss,of $6.2 ... period in,2007. Class A common shares outstanding on April ...
    ... Genetics,Inc. (Amex: ILI ), today expressed praise ... Nondiscrimination Act (GINA). The bill was approved,unanimously in ... into law by,President George W. Bush today., ... are protected,from genetic discrimination from employers and insurance ...
    ... The New Best Practice Statements Were Presented at ... YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, May ... cryotherapy, announced today that the,American Urological Association has ... cryotherapy. The guidelines state,that cryoablation is a treatment ...
    Cached Biology Technology:Biopure Announces 2008 Second Quarter Financial Results 2Biopure Announces 2008 Second Quarter Financial Results 3Biopure Announces 2008 Second Quarter Financial Results 4Biopure Announces 2008 Second Quarter Financial Results 5Biopure Announces 2008 Second Quarter Financial Results 6Biopure Announces 2008 Second Quarter Financial Results 7Biopure Announces 2008 Second Quarter Financial Results 8Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 2Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 3American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 2American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 3
    (Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
    (Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
    (Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... brains are under intensive development all over the ... areas, according to a study just placed online. ... of Southern California chaired the eight-member committee which ... in Brain-Computer Interfaces," published in October by the ...
    ... Conn. A before-and-after study led by Yale biologists, ... genetic diversity of marine iguanas on the Galpagos Islands, ... the need to determine which environmental and biological factors ... to the authors, recurring El Nio events provide an ...
    ... Ossur, an emerging leader in the non-invasive orthopaedics ... is pleased to announce that the Journal of Trauma ... cervical collar study performed by the Mayo Clinic. The ... from Four Cervical Collars, finds that Ossurs products ...
    Cached Biology News:Brain-computer link systems on the brink of breakthrough, study finds 2Global climate change: The impact of El Nio on Galpagos marine iguanas 2Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2
    Animal Origin Free...
    Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
    Request Info...
    ... Kits are designed for ultra-sensitive detection ... or PVDF membranes. Since all necessary ... primary antibodies), the WesternBreeze Kits save ... protocol and getting your final results. ...
    Biology Products: